SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q4 FY19 results · Jan–Mar 2019
SMS Pharmaceuticals reported revenue from operations of ₹103.71 crore and net profit of ₹6.48 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 103.71 | — | — | — | — |
| Other income | 0.75 | — | — | — | — |
| Total income | 104.46 | — | — | — | — |
| Profit before tax | 8.33 | — | — | — | — |
| Net profit for the period | 6.48 | — | — | — | — |
| EPS, basic (₹) | 0.76 | — | — | — | — |
| Net margin (%) | 6.2 | — | — |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 103.71 | — | — | 101.25 | +2.4% |
| Other income | 0.75 | — | — | 0.59 | +26.2% |
| Total income | 104.46 | — | — | 101.85 | +2.6% |
| Profit before tax | 8.33 | — | — | 18.64 | −55.3% |
| Net profit for the period | 6.48 | — | — | 12.19 | −46.9% |
| EPS, basic (₹) | 0.76 | — | — | 1.44 | −47.2% |
| Net margin (%) | 6.2 | — | 12.0 |
Consolidated
- Filed with BSE
- 30 May 2019, 14:39 IST
- Board meeting
- 27 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 May 2019, 14:33 IST
- Board meeting
- 27 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE